SCHEMBL25802170

SCHEMBL25802170

CCOP(C)(=O)C(Cc1nc(-c2ccc(OC3CCC3)cc2)no1)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.39
TP53 P04637 2/20 0.38
MITF O75030 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
POLB P06746 1/20 0.37
LMNA P02545 5/20 0.37
MAPK1 P28482 2/20 0.37
MAPT P10636 2/20 0.37
TSHR P16473 2/20 0.36
HTT P42858 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 2/20 0.35
ATM Q13315 2/20 0.35
HDAC4 P56524 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23578561 0.92 GPR119 (0.39) GPR119TP53MITFNCOA3POLB
SCHEMBL25802138 0.85 LMNA (0.48) LMNAMAPK1MAPTTSHRHTT
SCHEMBL25801943 0.84 ACACB (0.45) TP53MITFNCOA3POLBLMNA
SCHEMBL25801755 0.84 HTT (0.48) TP53LMNAMAPK1MAPTTSHR
SCHEMBL25802128 0.84 LMNA (0.39) TP53MITFNCOA3LMNAMAPK1
SCHEMBL25802131 0.84 LMNA (0.39) GPR119TP53MITFNCOA3LMNA
SCHEMBL25801989 0.84 SPHK1 (0.40) GPR119TP53MITFNCOA3LMNA
SCHEMBL25801976 0.81 CYP1A2 (0.39) TP53MITFNCOA3LMNAMAPK1
SCHEMBL25801780 0.81 SPHK1 (0.43) TP53MITFNCOA3POLBLMNA
SCHEMBL25801802 0.80 SPHK1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 GPR119 2548/4885TP53 2221/4885MITF 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.